Loading patent…
AssigneeCelldex Therapeutics, Inc.
InventorsYaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry
Estimating the term…
Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.
An isolated antibody, or an antigen-binding fragment thereof, which immunospecifically binds to a D4 region of human KIT, comprising:
An isolated antibody, or an antigen-binding fragment thereof, which immunospecifically binds to a D4 region of human KIT, comprising:
An isolated antibody or antigen-binding fragment thereof, which immunospecifically binds to a D4 region of human KIT, wherein said antibody or antigen-binding fragment thereof comprises:
An isolated antibody or antigen-binding fragment thereof, which immunospecifically binds to a D4 region of human KIT, wherein said antibody or antigen-binding fragment thereof comprises:
Dependencies are inferred from the claim text.